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eleterious Effect of
ltered Myocardial Fatty Acid
etabolism in Kidney Disease*
asken Dilsizian, MD, FACC,†
effrey C. Fink, MD, MS, FASN‡
altimore, Maryland
etabolic adaptation likely represents one of the earliest
esponses to myocardial ischemia. The myocardium prefer-
ntially oxidizes free fatty acids for energy production.
owever, the dependency of fatty acid metabolism on
xygen makes this process particularly vulnerable to ische-
ia. Under hypoxemic or ischemic conditions, the energy
equirements of the myocardium are met by glucose rather
han free fatty acids. Furthermore, recovery of fatty acid
etabolism after myocardial ischemia lags behind restora-
ion of perfusion, resulting in the phenomenon of “meta-
olic stunning.” This decrease in fatty acid utilization
ollowing ischemia can be imaged with fatty acid radiotrac-
rs, particularly -methyl iodophenyl-pentadecanoic acid
BMIPP), which demonstrate markedly limited metabolism
See page 139
ia beta oxidation, resulting in prolonged retention in the
ardiomyocyte (1,2). Thus, abnormal myocardial BMIPP
ptake at rest reflects metabolic alteration caused by the
receding ischemia, also termed “ischemic memory.” There
s reason to believe that such a relationship between cardiac
schemia and metabolism is accentuated in patients with
hronic kidney disease (CKD). In this issue of the Journal,
ishimura et al. (3) demonstrate the deleterious effect of
ltered metabolism in relationship to ischemia among patients
ith end-stage renal disease (ESRD) with a report of a
ignificant association between abnormal BMIPP uptake (in-
icating myocardial ischemia) and subsequent cardiac death
mong asymptomatic dialysis patients without history of prior
yocardial infarction (MI).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Diagnostic Radiology, Division of Nuclear Medicinep
nd the ‡Department of Medicine, Division of Nephrology, University of Maryland,
chool of Medicine, Baltimore Maryland.revalence of Cardiovascular Disease in CKD
ardiovascular disease accounts for most of the morbidity
nd mortality in both the predialysis stages of CKD and
fter the onset of ESRD. Chronic kidney disease is common
n the U.S. with almost 17% of adults older than 20 years
aving impaired renal function or urinary protein excretion
4). This is largely due to the rising frequency of hyperten-
ion and type 2 diabetes, which are the most common causes
f CKD among Americans. It has been reported that those
ho suffer from ESRD, and receive some form of dialysis,
ave as much as a 100-fold higher risk of death from
ardiovascular disease than healthy people matched for age,
ace, and gender (5). Beyond ischemic heart disease, con-
estive heart failure accounts for a significant portion of the
ardiovascular-related events observed in CKD.
Several sequelae of kidney failure that accrue with loss of
enal function can contribute to the myocardial remodeling
nd heart failure seen with the uremic variant of cardiomy-
pathy (Fig. 1). Elevated blood pressure, for example,
ecomes increasingly volume dependent with a concomitant
ncrease in arterial stiffening, activation of neurohormones,
nd endothelial dysfunction as renal function declines.
ndividuals with CKD, therefore, are faced with both
ressure- and volume-overload states contributing to the
evelopment of left ventricular hypertrophy (6). Addition-
lly, CKD is associated with excess parathyroid hormone
7,8), anemia (9), and high angiotensin II levels (10) that are
lso likely to contribute to myocardial injury.
etabolic Alterations
n CKD and Uremic Cardiomyopathy
ith the diffusely ischemic and oxygen-poor milieu de-
cribed with uremic cardiomyopathy, one might expect a
ecline in myocardial fatty acid utilization and a shift to
naerobic glucose metabolism. Disturbances of calcium and
hosphorus metabolism and a secondary increase in circu-
ating parathyroid hormone levels have been proposed as
ne possible mechanism in modulating myocardial growth
nd structure in uremic cardiomyopathy (8). In isolated
yocardial mitochondria, parathyroid hormone was shown
o inhibit myocardial energy production from long- and
hort-chain fatty acids and to uncouple oxidative phosphor-
lation (11). Because uptake of BMIPP in the myocardium
eflects activation of fatty acids by coenzyme A, and indi-
ectly of cellular adenosine triphosphate (ATP) production,
eduction in ATP production secondary to diminished fatty
cid metabolism is mirrored by decreased myocardial
MIPP uptake (12). Consequently, unless the myocytes
ompensate for the decreased fatty acid metabolism by
witching to anaerobic glycolysis for ATP formation, myo-
ellular cell death will ensue.
The relationship between myocardial glucose utilization
nd severity of renal dysfunction was recently reported in
re-dialysis CKD patients (13). Among nondiabetic CKD
atients without overt coronary artery disease (CAD), there
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January 15, 2008:146–8 Editorial Commentas a significant inverse correlation between myocardial
lucose utilization (measured in mol/min/100 g of myo-
ardial tissue) and glomerular filtration rate (Spearman’s
ho  0.67, p  0.008). In the future, dynamic fluoro-
eoxyglucose positron emission tomography (PET) may
rovide a sensitive, noninvasive, quantitative tool for inves-
igating subclinical myocardial abnormalities in patients
ith CKD.
yocyte–Capillary Mismatch
nd High Angiotensin II Levels in CKD
he cardiomyopathy typical of CKD and the associated
remia is thought to lead to a myocyte-capillary mismatch,
ith a diminished vascular supply relative to the number
nd volume of functioning myocytes (14). Autopsy exami-
ations of hearts from patients with CKD as well as
ndomyocardial biopsies of dialysis patients with cardiomy-
pathy have shown a substantial degree of myocyte disarray
nd interstitial fibrosis (15,16). It is now well established
hat the renin-angiotensin system (RAS) and its primary
ffector peptide, angiotensin II, are locally produced in the
eart and are implicated in the pathophysiology of intersti-
ial fibrosis, left ventricular remodeling, and heart failure.
he discovery of tissue RAS has promoted the development
f PET tracers targeting angiotensin-converting enzyme
ACE). Recently in explanted cardiac tissues from pa-
ients with ischemic cardiomyopathy, a specific binding
f [18F]fluorobenzoyl-lisinopril to tissue ACE was shown
17). ACE binding in peri-infarct segments was greater
han binding in remote, noninfarct segments. If reproduced
n vivo, this imaging technique sets the stage for future
robes that target the ACE system in the heart and kidney,
ith the potential of monitoring both the progression of left
entricular remodeling in CKD and the effect of medical
nd interventional therapies in such patients. Delayed en-
Figure 1 Concurrent Pathogenic Factors Contributing to Altered
Metabolism With Declining Kidney Function in CKD
Progression of CKD leads to metabolic remodeling of the heart. CHF  congestive
heart failure; CKD  chronic kidney disease; LVH  left ventricular hypertrophy.ancement with cardiac magnetic resonance and myocardial lissue characterization with echocardiography have also
hown changes consistent with myocardial injury and fibro-
is unique to kidney patients (18,19).
linical Studies With BMIPP in ESRD
n a recent prospective study of 130 asymptomatic ESRD
atients undergoing hemodialysis, Nishimura et al. (20)
nvestigated the prevalence of CAD by performing dual
sotope thallium and BMIPP single-photon emission
omputed tomography (SPECT) at rest followed by
oronary angiography. Significant coronary artery lumi-
al narrowing (75%) was present in 71% of ESRD
atients. When a reduced myocardial metabolism with
MIPP summed score of 6 was used to define an
bnormal scan, the sensitivity, specificity, and accuracy
or detecting CAD with rest BMIPP SPECT was 98%,
6%, and 90%, respectively (20).
In this issue of the Journal (3), the same investigators have
xamined the prognostic significance of reduced myocardial
etabolism with BMIPP in conjunction with perfusion
bnormalities assessed with thallium in ESRD patients
ithout prior MIs. Among the 318 prospectively enrolled
symptomatic hemodialysis patients, 50 (16%) died of
ardiac events during a mean follow-up period of 3.6  1.0
ears. Stepwise Cox hazard analysis showed that cardiac
eath was significantly associated with highly abnormal
MIPP uptake (summed score of 12; hazard ratio 
1.9) and age (70 years; hazard ratio  2.4). Among
atients with summed BMIPP scores of 12, event-free
urvival at 3 years was 61%, whereas event-free survival was
8% in those with summed BMIPP scores of 12. When
MIPP uptake (metabolism) was assessed in relation to
egional thallium uptake (perfusion), indicating myocardial
schemia, the sensitivity and specificity of the metabolism–
erfusion mismatch for predicting cardiac death was 86%
nd 88%, respectively. Among patients with BMIPP–
hallium mismatch scores of 7, event-free survival at 3
ears was 53%, whereas event-free survival was 96% in those
ith BMIPP:thallium mismatch scores of 7. These find-
ngs support the assertion that altered cardiac metabolism
indicating silent myocardial ischemia) is highly prevalent
n ESRD patients and can identify subgroups of patients
ho are at high risk for cardiac death. The shift from a
redominance of aerobic (fatty acid) to anaerobic (glu-
ose) metabolism appears to account for a significant
ortion of the excessive cardiovascular morbidity and
ortality observed across all stages of kidney disease.
otential limitations of the study include the relatively
igh mean age of the patients and the possibility that
ome of the deaths may have been caused by hyperkalemia
r other metabolic disorders rather than myocardial ische-
ia or coronary artery event.
Because patients with histories of MI were excluded from
he study, myocardial ischemia was implicated as the most
ikely explanation for the highly abnormal BMIPP SPECT
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Editorial Comment January 15, 2008:146–8ndings. Support for the latter comes from a recent publi-
ation that showed that patients without prior MIs who
nderwent clinically indicated exercise thallium SPECT
ollowed by rest BMIPP SPECT (2). The location and
xtent of myocardial ischemia as determined by reversible
hallium defects were correctly identified with BMIPP
maging during the subacute phase, at rest, and up to 30 h
fter the ischemic event. There was excellent patient-level
greement (90%) between BMIPP and thallium data for
he presence or absence of a scintigraphic abnormality.
urthermore, there was also good correlation between the
xtent and severity of the stress thallium defect and rest
MIPP defect when summed segmental scores were
pplied (2).
ummary
n asymptomatic hemodialysis patients with ESRD, im-
aired myocardial fatty acid metabolism assessed by BMIPP
PECT was used to identify the subgroup of patients who
ere at high risk for cardiac death. In the future, large
linical trials could provide further insight into the potential
trengths of this metabolic agent as a target for ischemic
emory and as a predictor of cardiac death. Targeting
ntracellular metabolic processes for imaging may expand
ur ability to diagnose and treat subclinical myocardial
schemia or progressive cardiomyopathy that often remains
lusive with traditional imaging approaches.
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